Endocrine therapy with tamoxifen or aromatase inhibitors (AIs) remains the cornerstone of adjuvant treatment for early-stage HR+ BC, with a standard treatment duration of five years [4,5,6]. The gene discussed is CYP19A1; the disease is breast cancer.